Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.
暂无分享,去创建一个
P Pezzotti | A Cozzi-Lepri | A N Phillips | M. Moroni | G. Ippolito | A. Phillips | S. Pauluzzi | F. Dianzani | P. Pezzotti | A. Monforte | C. Perno | C. Balotta | A. Bertoli | G. Tositti | G. Angarano | A. Cozzi-Lepri | M Moroni | L. Monno | F. Forbici | G Ippolito | G Angarano | C F Perno | A Bertoli | C Balotta | F Forbici | M Violin | G Facchi | G Cadeo | G Tositti | S Pasquinucci | S Pauluzzi | A Scalzini | B Salassa | A Vincenti | F Dianzani | A Appice | L Monno | A d' Arminio Monforte | A. Appice | M. Violin | G. Facchi | G. Cadeo | A. Scalzini | B. Salassa | A. Vincenti | A. d' Arminio Monforte | C. Perno | S. Pasquinucci | G. Cadeo | Giulio Tositti
[1] K. Tashima,et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. , 1999, The New England journal of medicine.
[2] J. Pagano,et al. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy. , 1994, The Journal of infectious diseases.
[3] R. Colonno,et al. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[4] Remco,et al. pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D , 1997, Journal of virology.
[5] J. Rockstroh,et al. Reply: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. , 1997, AIDS.
[6] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[7] S D Kemp,et al. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.
[8] M. Mouroux,et al. Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor , 1999, Journal of Clinical Microbiology.
[9] S. Little. Transmission and Prevalence of HIV Resistance among Treatment-Naive Subjects , 2000, Antiviral therapy.
[10] M. Kazatchkine,et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. , 1999, AIDS.
[11] E. Arnold,et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[12] H. B. Schock,et al. Mutational Anatomy of an HIV-1 Protease Variant Conferring Cross-resistance to Protease Inhibitors in Clinical Trials , 1996, The Journal of Biological Chemistry.
[13] J. Martinez-Picado,et al. Replicative Fitness of Protease Inhibitor-Resistant Mutants of Human Immunodeficiency Virus Type 1 , 1999, Journal of Virology.
[14] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.
[15] H. Mitsuya,et al. Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay , 1999, Journal of Virology.
[16] B. Efron,et al. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons. , 1999, The Journal of infectious diseases.
[17] JD Lundgren,et al. Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.
[18] P. McCullagh,et al. Generalized Linear Models , 1992 .
[19] J. Montaner,et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.
[20] B Wise,et al. Antiretroviral therapy in adults. , 1996, Journal of the American Academy of Nurse Practitioners.
[21] D V Glidden,et al. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. , 2000, The Journal of infectious diseases.
[22] B. Larder,et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. , 1992, The Journal of infectious diseases.
[23] T. Merigan,et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy , 2000 .
[24] Robert Shafer,et al. HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed , 1999, Annals of Internal Medicine.
[25] D. Katzenstein,et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. , 1994, The Journal of infectious diseases.
[26] M. Moroni,et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients , 2000, AIDS.
[27] D. R. Kuritzkes,et al. Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.
[28] T. Merigan,et al. Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients , 1998, Annals of Internal Medicine.
[29] D. Richman,et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. , 1998, JAMA.
[30] D. Venzon,et al. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. , 1998, The Journal of infectious diseases.
[31] J. Ioannidis,et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. , 1998, The New England journal of medicine.
[32] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[33] P. Harrigan,et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. , 1999, AIDS.
[34] J. Fitzgibbon,et al. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine , 1992, Antimicrobial Agents and Chemotherapy.
[35] M. Wainberg,et al. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase , 1993, Antimicrobial Agents and Chemotherapy.
[36] T. Merigan,et al. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations. , 1999, AIDS.
[37] V. Calvez,et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). , 2000, JAMA.
[38] M. Lederman,et al. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. , 2000, The Journal of infectious diseases.
[39] M A Fischl,et al. Antiretroviral Therapy in Adults Updated Recommendations of the International AIDS Society–USA Panel , 2000 .
[40] D. Ho,et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.
[41] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[42] D. Richman,et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. , 1989, Science.
[43] S. Hammer,et al. The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.
[44] B. Larder,et al. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.